Drug Stocks To Watch For Earnings On Aug 9: MYL, INCY & More
Zacks Investment Research | Aug 07, 2016 10:05PM ET
The Q2 earnings season is almost approaching its end with 87.7% (as of Aug 5) of the S&P 500 members having already reported results. The Retail sector is the only one at this point that has a substantial number of reports still to come.
But how has this particular earnings season turned out to be? Though the Q2 growth pace pace has “improved” with companies reporting better results, still the quarter is on its way to be the fifth in a row to record an earnings decline for the S&P 500 index. So far, of the 433 S&P 500 companies that have reported as of Aug 5, 70.7% breezed past earnings expectations while 52.7% exceeded revenue estimates.
Results in the Technology and Medical sectors have been remarkably better than anticipated. These two sectors have also recorded the highest proportion of positive surprises.
Particularly, our Q2 scorecard for the Medical sector shows that 86.5% have reported results with a blended beat of 77.8% (the percentage of companies that have beaten both earnings per share as well as revenue estimates) with the sector posting 6.5% earnings growth on revenue growth of 9.9%.
Per our Earnings Trends report, Medical is one of the eight sectors expected to record earnings growth in Q2.
Among drug stocks lined up to report on Aug 9, let’s take a look at three such companies.
What to Expect from these Drug Stocks?
Generic drug maker, Mylan N.V.’s (NASDAQ:MYL) performance has been impressive with the company beating earnings estimates in three of the last four quarters with an average positive surprise of 1.79%. Mylan currently carries a Zacks Rank #3 (Hold). Though the stock’s Zacks Rank #3 increases the predictive power of the ESP, it also has an Mylan Q2 Earnings: Will the Stock Disappoint? ).
Oncology focused Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company with a pretty good track record having surpassed expectations in three of the last four quarters with an average positive surprise of 101.83%. Headquartered in Wilmington, DE, Incyte has a favorable Zacks Rank #2 (Buy), but an ESP of 0.00% makes a surprise prediction uncertain this quarter. The company’s only approved product, Jakafi, should continue to drive top-line growth in this quarter as well. Meanwhile, Incyte has a broad pipeline including both targeted and immune therapies. Update on the pipeline front will be another area of focus along with the performance of Jakafi. The company is scheduled to release Q2 results on Aug 9.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.